Sign in
Not yet taking people in United StatesPhase 3

Tests oral ORMD-0801 capsules in adults with type 2 diabetes

Tests an oral capsule, ORMD-0801, in adults with type 2 diabetes not well controlled.

Key facts

Who runs it
Oramed, Ltd.
Where
Dallas, United StatesSee the site
Trial code
Registry title
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
Status
Not yet recruiting
Phase
Phase 3
People taking part
300 people, planned
Started
15 Dec 2025
Expected to end
22 May 2027
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ORMD-0801 8 mg
  • Placebo capsule
  • ORMD-0801 16 mg
Record updated
3 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 or older with type 2 diabetes whose blood sugar is still too high on one to three glucose-lowering medicines.

Age
50 years or older
Sex
Men and women can join
Disease stage
Type 2 diabetes for at least 6 months, with A1C ≥ 7.2% (55 mmol/mol) but ≤ 10.0% (86 mmol/mol) at Screening, and eGFR ≥ 30 ml/min.
Earlier treatment
Must have taken a stable dose of one to three glucose-lowering medicines (for example metformin, sulfonylurea, DPP-4 inhibitor, SGLT-2 inhibitor) for at least 3 months before Screening. Injected insulin is excluded.

Main reasons for not taking part

  • Type 1 diabetes, or diabetes caused by another condition
  • Injected insulin within 3 months before Visit 1
  • Heart problems, stroke or mini-stroke within 6 months before Screening
  • Positive test for HIV, hepatitis B or hepatitis C
  • Pregnant or breast-feeding

The registry criteria, word for word

Show all 45 criteriaShow less

Who can take part

  • Male and female subjects aged ≥ 50 years
  • Established diagnosis of T2DM for at least 6 months prior to Screening AND an A1C ≥ 7.2% but ≤ 10.0% at Screening
  • On a stable dose of at least one and up to three of the following glucose-lowering agents: Metformin, sulfonylurea, DPP-4 inhibitor, SGLT-2 inhibitor, thiazolidinedione, insulin secretagogue, oral or injected GLP-1 receptor agonists, glucosidase inhibitor, or pramlintide (injected insulin is excluded) for a minimum of 3 months prior to Screening
  • Body mass index (BMI) of ≤ 28 kg/m2 at Screening and stable weight, with no more than 5 kg gain or loss in the 3 months prior to Screening
  • Renal function - eGFR ≥ 30 ml/min
  • Females of childbearing potential must:
  • - a. Have a negative serum pregnancy test result at Screening
  • - b. Agree to avoid becoming pregnant while receiving IP for at least 30 days prior to IP administration, during the entire study, and for 30 days following their last dose of IP
  • - c. Agree to use an acceptable method of contraception at least 30 days prior to IP administration, during the entire study, and for 30 days following their last dose of IP. Acceptable methods of contraception are hormonal contraception (contraceptive pill or injection) PLUS an additional barrier method of contraception such as a diaphragm, condom, sponge, or spermicide
  • - d. In the absence of hormonal contraception, double-barrier methods must be used which include a combination of any two of the following: diaphragm, condom, copper intrauterine device, sponge, or spermicide, and must be used for at least 30 days prior to administration of IP, during the entire study, and for 30 days following their last dose of IP
  • - e. Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if it is consistently employed as the subject's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ERCs/IRBs. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception
  • - f. Females who are not of childbearing potential are defined as:
  • - - - - - i. Postmenopausal (defined as at least 12 months with no menses in women ≥ 45 years of age); OR
  • - - - - - ii. Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; OR
  • - - - - - iii. Have a congenital or acquired condition that prevents childbearing

Who cannot take part

  • Treatment involving injected insulin within 3 months prior to Visit 1
  • A history of > 2 episodes of severe hypoglycemia within 6 months prior to Screening
  • A history of unstable angina or myocardial infarction within 6 months prior to Screening, New York Heart Association (NYHA) Grade 3 or 4 congestive heart failure (CHF), valvular heart disease, ventricular cardiac arrhythmia requiring treatment, pulmonary hypertension, cardiac surgery, coronary angioplasty, stroke, or transient ischemic attack (TIA) within 6 months prior to Screening
  • Patient has active or history of neoplastic disease (except for adequately treated non-invasive basal cell and/or squamous cell carcinoma or carcinoma in situ of the cervix) within the past 5 years prior to baseline
  • Use of the following medications:
  • - - -a. History of use of any injectable insulin (greater than 7 days) within 6 months prior to Screening
  • - - -b. Administration of thyroid preparations or thyroxine (except in subjects on stable replacement therapy) within 6 weeks prior to Screening
  • - - - c. Use of oral, intravenous, or intramuscular steroids for one month prior to enrollment. Intra-articular and/or topical corticosteroids are not considered systemic
  • Involvement in a weight loss program and is not in the maintenance phase, or subject has started weight loss medication (e.g., orlistat or liraglutide) within 3 months prior to Screening
  • Prior bariatric surgery
  • Subject is a user of recreational or illicit drugs or has had a recent history (within 1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by > 3 drinks per day or > 14 drinks per week or binge drinking) at Screening. Occasional intermittent use of cannabinoid products will be allowed provided that no cannabinoid products have been used during the 1 week prior to each visit
  • Type 1 diabetes by history
  • Diabetes attributable to other secondary causes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant)
  • A history of hypoglycemic unawareness
  • A history of uncontrolled or untreated severe hypertension defined as systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg. A single repeat measurement will be permitted
  • A history of or active proliferative retinopathy requiring treatment
  • Psychiatric disorders that, per Investigator judgment, may have impact on the safety of the subject or interfere with subject's participation or compliance in the study
  • Positive history of active liver disease (other than non-alcoholic hepatic steatosis), primary biliary cirrhosis, or active symptomatic gallbladder disease
  • Positive results for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus ribonucleic acid (RNA)
  • Known allergy to soy
  • Weight loss preparations either approved and marketed or used in OTC preparations except for GLP-1 used in the treatment of underlying diabetes
  • Any condition or other factor (at the Investigator's discretion) that is deemed unsuitable for subject enrollment into the study
  • Renal dysfunction: eGFR < 30 mL/min
  • Laboratory abnormalities at Screening including:
  • - - a. Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or >1.5X the upper limit of normal; a single repeat test is allowable
  • - - b. Elevated liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)) > 3X the upper limit of normal; a single repeat test is allowable
  • - - c. Very elevated fasting triglyceride levels (> 600 mg/dL); a single repeat test is allowable
  • - - - d. Concurrent use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and immunosuppressive or immunomodulating agents. Inhaled nasal steroids are permissible
  • - - d. Any relevant abnormality that would interfere with the efficacy or the safety assessments during study treatment administration
  • Subject is pregnant or breast-feeding

Where in United States

  • Velocity Clinical Research, DallasDallas, United StatesContact: Kathleen CrawfordNot yet recruiting

About the trial

What the trial wants to find out

ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2 Diabetes Mellitus (T2DM) who have not responded well to other glucose-lowering medications. A total of three hundred subjects will be enrolled in this study and will be required to complete this thirty-four-week clinical trial.

The 4 groups in the trial

  • ORMD-0801 8 mg once-daily at night - QDExisting treatment, for comparison

    Double-Dummy; the subject receives both experimental drug and placebo. 1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).

    Treatment: ORMD-0801 8 mg and Placebo capsule

  • ORMD-0801 8 mg twice daily - BIDExisting treatment, for comparison

    Double-Dummy; the subject receives both experimental drug and placebo. 1 x 8 mg capsule each morning approximately 45 minutes (±15 minutes) prior to breakfast and 1 x 8 mg capsule each night prior to bedtime (between 8 PM to 12 Midnight and no sooner than 1 hour after dinner) and 1 placebo capsule at night.

    Treatment: ORMD-0801 8 mg and Placebo capsule

  • ORMD-0801 16 mg once-daily at night - QDExisting treatment, for comparison

    Double-Dummy; the subject receives both experimental drug and placebo. 2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.

    Treatment: Placebo capsule and ORMD-0801 16 mg

  • PlaceboPlacebo, for comparison

    The subject receives 3 placebo capsules.

    Treatment: Placebo capsule

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on One to Three Glucose-lowering Agents
Plain-language title
Tests oral ORMD-0801 capsules in adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 August 2025